Jay Rothstein,Robert George Edward Holgate,Arron Hearn
申请号：
US15744379
公开号：
US20180193454A1
申请日:
2016.07.13
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.
